8.7(top 1%)
Impact Factor
9.2(top 1%)
extended IF
89(top 4%)
H-Index
2.3K
authors
2.2K
papers
60.6K
citations
3.8K
citing journals
36.5K
citing authors

Most Cited Articles of Cardiovascular Diabetology

TitleYearCitations
Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-20172018580
Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice2005568
Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease2006477
Association between insulin resistance and the development of cardiovascular disease2018472
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus2014313
How hyperglycemia promotes atherosclerosis: molecular mechanisms2002291
Endothelial dysfunction: a comprehensive appraisal2006277
Clinical usefulness of lipid ratios, visceral adiposity indicators, and the triglycerides and glucose index as risk markers of insulin resistance2014218
On the use of a continuous metabolic syndrome score in pediatric research2008213
Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice2014212
Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study2017189
Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme2012188
Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies2018187
Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons2005180
Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes2017171
Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes2011170
Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus2013164
Diabetes, cardiovascular disease and the microcirculation2018162
SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart2019161
Beneficial effects of a Paleolithic diet on cardiovascular risk factors in type 2 diabetes: a randomized cross-over pilot study2009155
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)2014153
The effect of dapagliflozin treatment on epicardial adipose tissue volume2018147
Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome2005144
Regular physical exercise training assists in preventing type 2 diabetes development: focus on its antioxidant and anti-inflammatory properties2011143
Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products2006143